Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Hypercholesterolemia-Pipeline Review, H1 2015

Hypercholesterolemia-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Hypercholesterolemia-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Hypercholesterolemia-Pipeline Review, H1 2015', provides an overview of the Hypercholesterolemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Hypercholesterolemia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Hypercholesterolemia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Hypercholesterolemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Hypercholesterolemia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Hypercholesterolemia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Hypercholesterolemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Hypercholesterolemia Overview 9

Therapeutics Development 10

Pipeline Products for Hypercholesterolemia-Overview 10

Pipeline Products for Hypercholesterolemia-Comparative Analysis 11

Hypercholesterolemia-Therapeutics under Development by Companies 12

Hypercholesterolemia-Therapeutics under Investigation by Universities/Institutes 16

Hypercholesterolemia-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Hypercholesterolemia-Products under Development by Companies 21

Hypercholesterolemia-Products under Investigation by Universities/Institutes 26

Hypercholesterolemia-Companies Involved in Therapeutics Development 27

Aegerion Pharmaceuticals, Inc. 27

Alnylam Pharmaceuticals, Inc. 28

Amgen Inc. 29

AtheroNova Inc. 30

Bristol-Myers Squibb Company 31

Catabasis Pharmaceuticals, Inc. 32

Cerenis Therapeutics Holding SA 33

CrystalGenomics, Inc. 34

CymaBay Therapeutics, Inc. 35

Daewon Pharm Co. Ltd. 36

Dybly AG 37

Eli Lilly and Company 38

Esperion Therapeutics, Inc. 39

F. Hoffmann-La Roche Ltd. 40

Hanmi Pharmaceuticals, Co. Ltd. 41

Immune Response BioPharma, Inc. 42

Johnson & Johnson 43

Kadmon Corporation, LLC 44

Kowa Company, Ltd. 45

Merck & Co., Inc. 46

Michigan Life Therapeutics, LLC 47

Novartis AG 48

Pfizer Inc. 49

Planet Biotechnology Inc. 50

Regeneron Pharmaceuticals, Inc. 51

Sanofi 52

Serometrix, LLC 53

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 54

Thetis Pharmaceuticals LLC 55

uniQure N.V. 56

Zhejiang Hisun Pharmaceutical Co., Ltd. 57

Hypercholesterolemia-Therapeutics Assessment 58

Assessment by Monotherapy Products 58

Assessment by Combination Products 59

Assessment by Target 60

Assessment by Mechanism of Action 63

Assessment by Route of Administration 66

Assessment by Molecule Type 68

Drug Profiles 70

(aspirin + lisinopril + lovastatin)-Drug Profile 70

(ezetimibe + atorvastatin calcium)-Drug Profile 71

AEM-28-Drug Profile 72

AEM-28-02-Drug Profile 73

AHRO-001-Drug Profile 74

alipogene tiparvovec-Drug Profile 76

alirocumab-Drug Profile 78

ALN-PCSsc-Drug Profile 82

AM-0010-Drug Profile 83

anacetrapib-Drug Profile 84

Antisense Oligonucleotide to Target miR-33 for Cardiovascular Diseases-Drug Profile 86

Antisense Oligonucleotides to Inhibit ApoB100 for Familial Hypercholesterolemia-Drug Profile 87

aplexone-Drug Profile 88

bempedoic acid-Drug Profile 89

BMS-962476-Drug Profile 91

bococizumab-Drug Profile 92

BSN-272-Drug Profile 93

CAT-2003-Drug Profile 94

CAT-2054-Drug Profile 95

CER-001-Drug Profile 96

Drugs to Inhibit Sortilin for Hypercholesterolemia-Drug Profile 98

DW-3102-Drug Profile 99

DYB-186-Drug Profile 100

EGF-AB Fc Variants to Inhibit PCSK9 for Hypercholesterolemia-Drug Profile 101

EP-80317-Drug Profile 103

evacetrapib-Drug Profile 104

evinacumab-Drug Profile 106

evolocumab-Drug Profile 107

fenofibrate-Drug Profile 110

gemcabene calcium-Drug Profile 112

Gene Therapy to Activate LDL Receptor for Homozygous Familial Hypercholesterolemia-Drug Profile 113

Gene Therapy to Inhibit PCSK9 for Hypercholesterolemia-Drug Profile 114

HCP-1306-Drug Profile 115

HS-25-Drug Profile 116

IR-1002-Drug Profile 117

J-17-Drug Profile 118

KD-026-Drug Profile 119

lomitapide mesylate-Drug Profile 121

LY-3015014-Drug Profile 123

MBX-8025-Drug Profile 124

MGL-3196-Drug Profile 126

mipomersen sodium-Drug Profile 128

Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia-Drug Profile 130

PCSK-9-Drug Profile 131

PF-06678552-Drug Profile 132

pitavastatin-Drug Profile 133

pitavastatin CR-Drug Profile 134

pradigastat sodium-Drug Profile 135

Small Molecule to Inhibit Endothelial Lipase for Hypercholesterolemia-Drug Profile 136

Small Molecule to Inhibit PCSK9 for Hypercholesterolemia-Drug Profile 137

Small Molecule to Inhibit PCSK9 for Hypercholesterolemia-Drug Profile 138

Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders-Drug Profile 139

Small Molecules to Inhibit PCSK9 for Hypercholesterolemia-Drug Profile 141

Small Molecules to Inhibit PCSK9 for Hypercholesterolemia-Drug Profile 142

SX-PCK9-Drug Profile 143

Synthetic Peptide for Hypercholesterolemia-Drug Profile 144

TP-452-Drug Profile 145

VK-0214-Drug Profile 146

volanesorsen sodium-Drug Profile 147

Hypercholesterolemia-Recent Pipeline Updates 148

Hypercholesterolemia-Dormant Projects 195

Hypercholesterolemia-Discontinued Products 200

Hypercholesterolemia-Product Development Milestones 202

Featured News & Press Releases 202

Appendix 211

Methodology 211

Coverage 211

Secondary Research 211

Primary Research 211

Expert Panel Validation 211

Contact Us 211

Disclaimer 212

List of Tables

Number of Products under Development for Hypercholesterolemia, H1 2015 14

Number of Products under Development for Hypercholesterolemia-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 17

Number of Products under Development by Companies, H1 2015 (Contd..1) 18

Number of Products under Development by Companies, H1 2015 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H1 2015 20

Comparative Analysis by Late Stage Development, H1 2015 21

Comparative Analysis by Clinical Stage Development, H1 2015 22

Comparative Analysis by Early Stage Development, H1 2015 23

Comparative Analysis by Unknown Stage Development, H1 2015 24

Products under Development by Companies, H1 2015 25

Products under Development by Companies, H1 2015 (Contd..1) 26

Products under Development by Companies, H1 2015 (Contd..2) 27

Products under Development by Companies, H1 2015 (Contd..3) 28

Products under Development by Companies, H1 2015 (Contd..4) 29

Products under Investigation by Universities/Institutes, H1 2015 30

Hypercholesterolemia-Pipeline by Aegerion Pharmaceuticals, Inc., H1 2015 31

Hypercholesterolemia-Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 32

Hypercholesterolemia-Pipeline by Amgen Inc., H1 2015 33

Hypercholesterolemia-Pipeline by AtheroNova Inc., H1 2015 34

Hypercholesterolemia-Pipeline by Bristol-Myers Squibb Company, H1 2015 35

Hypercholesterolemia-Pipeline by Catabasis Pharmaceuticals, Inc., H1 2015 36

Hypercholesterolemia-Pipeline by Cerenis Therapeutics Holding SA, H1 2015 37

Hypercholesterolemia-Pipeline by CrystalGenomics, Inc., H1 2015 38

Hypercholesterolemia-Pipeline by CymaBay Therapeutics, Inc., H1 2015 39

Hypercholesterolemia-Pipeline by Daewon Pharm Co. Ltd., H1 2015 40

Hypercholesterolemia-Pipeline by Dybly AG, H1 2015 41

Hypercholesterolemia-Pipeline by Eli Lilly and Company, H1 2015 42

Hypercholesterolemia-Pipeline by Esperion Therapeutics, Inc., H1 2015 43

Hypercholesterolemia-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 44

Hypercholesterolemia-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 45

Hypercholesterolemia-Pipeline by Immune Response BioPharma, Inc., H1 2015 46

Hypercholesterolemia-Pipeline by Johnson & Johnson, H1 2015 47

Hypercholesterolemia-Pipeline by Kadmon Corporation, LLC, H1 2015 48

Hypercholesterolemia-Pipeline by Kowa Company, Ltd., H1 2015 49

Hypercholesterolemia-Pipeline by Merck & Co., Inc., H1 2015 50

Hypercholesterolemia-Pipeline by Michigan Life Therapeutics, LLC, H1 2015 51

Hypercholesterolemia-Pipeline by Novartis AG, H1 2015 52

Hypercholesterolemia-Pipeline by Pfizer Inc., H1 2015 53

Hypercholesterolemia-Pipeline by Planet Biotechnology Inc., H1 2015 54

Hypercholesterolemia-Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 55

Hypercholesterolemia-Pipeline by Sanofi, H1 2015 56

Hypercholesterolemia-Pipeline by Serometrix, LLC, H1 2015 57

Hypercholesterolemia-Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2015 58

Hypercholesterolemia-Pipeline by Thetis Pharmaceuticals LLC, H1 2015 59

Hypercholesterolemia-Pipeline by uniQure N.V., H1 2015 60

Hypercholesterolemia-Pipeline by Zhejiang Hisun Pharmaceutical Co., Ltd., H1 2015 61

Assessment by Monotherapy Products, H1 2015 62

Assessment by Combination Products, H1 2015 63

Number of Products by Stage and Target, H1 2015 65

Number of Products by Stage and Mechanism of Action, H1 2015 68

Number of Products by Stage and Route of Administration, H1 2015 71

Number of Products by Stage and Molecule Type, H1 2015 73

Hypercholesterolemia Therapeutics-Recent Pipeline Updates, H1 2015 152

Hypercholesterolemia-Dormant Projects, H1 2015 199

Hypercholesterolemia-Dormant Projects (Contd..1), H1 2015 200

Hypercholesterolemia-Dormant Projects (Contd..2), H1 2015 201

Hypercholesterolemia-Dormant Projects (Contd..3), H1 2015 202

Hypercholesterolemia-Dormant Projects (Contd..4), H1 2015 203

Hypercholesterolemia-Discontinued Products, H1 2015 204

Hypercholesterolemia-Discontinued Products (Contd..1), H1 2015 205

List of Figures

Number of Products under Development for Hypercholesterolemia, H1 2015 14

Number of Products under Development for Hypercholesterolemia-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 16

Number of Products under Investigation by Universities/Institutes, H1 2015 20

Comparative Analysis by Late Stage Development, H1 2015 21

Comparative Analysis by Clinical Stage Development, H1 2015 22

Comparative Analysis by Early Stage Products, H1 2015 23

Assessment by Monotherapy Products, H1 2015 62

Number of Products by Top 10 Targets, H1 2015 64

Number of Products by Stage and Top 10 Targets, H1 2015 64

Number of Products by Top 10 Mechanism of Actions, H1 2015 67

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 67

Number of Products by Top 10 Routes of Administration, H1 2015 70

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 70

Number of Products by Top 10 Molecule Types, H1 2015 72

Number of Products by Stage and Top 10 Molecule Types, H1 2015 72

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Aegerion Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

Amgen Inc.

AtheroNova Inc.

Bristol-Myers Squibb Company

Catabasis Pharmaceuticals, Inc.

Cerenis Therapeutics Holding SA

CrystalGenomics, Inc.

CymaBay Therapeutics, Inc.

Daewon Pharm Co. Ltd.

Dybly AG

Eli Lilly and Company

Esperion Therapeutics, Inc.

F. Hoffmann-La Roche Ltd.

Hanmi Pharmaceuticals, Co. Ltd.

Immune Response BioPharma, Inc.

Johnson & Johnson

Kadmon Corporation, LLC

Kowa Company, Ltd.

Merck & Co., Inc.

Michigan Life Therapeutics, LLC

Novartis AG

Pfizer Inc.

Planet Biotechnology Inc.

Regeneron Pharmaceuticals, Inc.

Sanofi

Serometrix, LLC

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Thetis Pharmaceuticals LLC

uniQure N.V.

Zhejiang Hisun Pharmaceutical Co., Ltd.

Hypercholesterolemia Therapeutic Products under Development, Key Players in Hypercholesterolemia Therapeutics, Hypercholesterolemia Pipeline Overview, Hypercholesterolemia Pipeline, Hypercholesterolemia Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com